Related Experiment Videos
[Proposed criteria for diagnosis of celiac disease in children]
L Danielsson1, L Stenhammar, H Ascher
1Barn-och ungdomsmedicinska mottagningen, Norrtälje sjukhus.
Insights
A new diagnostic protocol for pediatric celiac disease was approved in Sweden, requiring small bowel biopsies for all children. This protocol streamlines diagnosis and management of celiac disease.
Area of Science:
- Pediatric Gastroenterology
- Immunology
- Gastrointestinal Diseases
Context:
- A 1997 seminar by the Swedish Paediatric Working Group for Coeliac Disease addressed diagnostic challenges.
- Existing diagnostic methods for pediatric celiac disease lacked standardization across Sweden.
Purpose:
- To establish a unified and efficient diagnostic protocol for pediatric celiac disease in Sweden.
- To standardize the approach to small bowel biopsies and serological testing.
Summary:
- A majority of Swedish pediatricians approved a new protocol requiring small bowel biopsies at presentation and during gluten-free diet follow-up for all children.
- Gluten challenge and repeat biopsy are reserved for atypical cases or future diagnostic uncertainty.
- Serum antigliadin and anti-endomysial antibody tests serve as complementary diagnostic tools.
Impact:
- Implementation of this protocol aims to improve diagnostic accuracy and consistency for pediatric celiac disease nationwide.
- The establishment of a national coeliac disease registry is planned to further enhance research and patient care.
- This standardized approach is expected to reduce diagnostic delays and improve outcomes for children with celiac disease.
Abstract:
At a seminar arranged in September 1997 by the Swedish Paediatric Working Group for Coeliac Disease, a diagnostic protocol proposed by the working group was approved by a majority of the paediatricians present, representing almost all paediatric units in Sweden. Briefly, a small bowel biopsy is called for in all children, both at presentation and as a control during gluten-free dieting. Subsequent gluten challenge and biopsy are mandatory only in cases of atypical presentation or if the diagnosis is questioned at some future date. Serum antigliadin and anti-endomysial antibody tests are complementary tools. Agreement was also reached regarding the institution of a national coeliac disease registry.